Hotta Tomomitsu | Department Of Hematology And Molecular Medicine Unit Atomic Bomb Disease Institute Nagasaki Universi

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
Pulmonary non-caseating granuloma in Waldenstrom macroglobulinemia
Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study
Clinical Effects of Infusing Anti-Epstein -Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes into Patients with Severe Chronic Active EBV Infection
Comparison of Soluble and Membrane Bound HLA-Class I and DR Levels in Umbilical Cord Blood and Adult Peripheral Blood
The Generation of Immunocompetent Dendritic Cells From CD34^+ Acute Myeloid or Lymphoid Leukemia Cells
Autografting with peripheral blood CD34-positive cells following high-dose chemotherapy against breast cancer
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-and low-intermediate risk, aggressive non-Hodgkin's lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG95

もっと見る

スポンサーリンク